noom glp 1 fda approved GLP-1rx Plus Program — Prescription Weight Loss Medication Online Noom's GLP-1 Companion Receives Major

As states cut Medicaid coverage for GLP-1 drugs, access to obesity treatment is increasingly tied to incomeraising questions for both Medicaid and Medicare.

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

Lively's HSA Spend Report shows consumers are increasingly using accounts for online wellness, mental health, and weight-loss products.

Here's what you can do about it.

PBH is characterized by postprandial hypoglycemia causing neuroglycopenic symptoms of confusion, loss of consciousness, and seizures in a smaller subset of patients